These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome in the intensive care unit: a case report. Belicard F; Belhomme N; Bouzy S; Saillard C; Nedelec F; Mear JB; Ardois S; Pastoret C; Reizine F; Camus C; Painvin B J Med Case Rep; 2023 Jul; 17(1):314. PubMed ID: 37480098 [TBL] [Abstract][Full Text] [Related]
8. VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases. Vitale A; Caggiano V; Bimonte A; Caroni F; Tosi GM; Fabbiani A; Renieri A; Bocchia M; Frediani B; Fabiani C; Cantarini L Intern Emerg Med; 2023 Apr; 18(3):711-722. PubMed ID: 36662445 [TBL] [Abstract][Full Text] [Related]
9. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome presenting as recurrent aseptic peritonitis in a patient receiving peritoneal dialysis: a case report. Fukuda N; Kanai D; Hoshino K; Fukuda Y; Morita R; Ishikawa Y; Kanaoka T; Toya Y; Kirino Y; Wakui H; Tamura K BMC Nephrol; 2024 Jan; 25(1):18. PubMed ID: 38212709 [TBL] [Abstract][Full Text] [Related]
10. VEXAS Syndrome-Review. Zhang Y; Dong X; Wang H Glob Med Genet; 2023 Sep; 10(3):133-143. PubMed ID: 37501758 [TBL] [Abstract][Full Text] [Related]
11. Budd-Chiari syndrome: a common complication of Behçet's disease. Bayraktar Y; Balkanci F; Bayraktar M; Calguneri M Am J Gastroenterol; 1997 May; 92(5):858-62. PubMed ID: 9149201 [TBL] [Abstract][Full Text] [Related]
12. Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. Goyal A; Narayanan D; Wong W; Laga AC; Connell NT; Ritter SY; Cobos G JAAD Case Rep; 2022 May; 23():15-19. PubMed ID: 35391910 [No Abstract] [Full Text] [Related]
14. A Case of VEXAS: Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic Syndrome With Co-existing DNA (Cytosine-5)-Methyltransferase 3A Mutation Complicated by Localized Skin Reaction to Tocilizumab and Azacitidine. Estes J; Malus M; Wilson L; Grayson PC; Maz M Cureus; 2023 Jun; 15(6):e39906. PubMed ID: 37404435 [TBL] [Abstract][Full Text] [Related]
15. Episcleritis and periorbital edema secondary to VEXAS syndrome. Fanlo P; Román MLS; Fonollosa A; Ilarramendi J; Heras H; Grayson P Arch Soc Esp Oftalmol (Engl Ed); 2023 Oct; 98(10):607-610. PubMed ID: 37595794 [TBL] [Abstract][Full Text] [Related]
16. VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge. Kreutzinger V; Pankow A; Boyadzhieva Z; Schneider U; Ziegeler K; Stephan LU; Kübke JC; Schröder S; Oberender C; le Coutre P; Stintzing S; Jelas I J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398362 [TBL] [Abstract][Full Text] [Related]
17. Clinical Manifestations in Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome: A Narrative Review. Padureanu V; Marinaș CM; Bobirca A; Padureanu R; Patrascu S; Dascalu AM; Bobirca F; Tribus L; Alexandru C; Serboiu C; Dumitrascu C; Musetescu A Cureus; 2024 Jan; 16(1):e53041. PubMed ID: 38410307 [TBL] [Abstract][Full Text] [Related]
18. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field. Phan L; Hammond D; Wilson NR; Groarke EM; Patnaik MM; Pemmaraju N Leuk Lymphoma; 2024 May; ():1-13. PubMed ID: 38770970 [TBL] [Abstract][Full Text] [Related]
19. VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease. Saad AJ; Patil MK; Cruz N; Lam CS; O'Brien C; Nambudiri VE Exp Dermatol; 2024 Mar; 33(3):e15050. PubMed ID: 38469984 [TBL] [Abstract][Full Text] [Related]
20. JAK inhibitors for the treatment of VEXAS syndrome. Bindoli S; Baggio C; Doria A; Bertoldo E; Sfriso P Exp Biol Med (Maywood); 2023 May; 248(5):394-398. PubMed ID: 37243340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]